ArticleJournal of ophthalmic & vision research2026
Unexplained Perivascular Chorioretinal Atrophy: Is Ranolazine a Possible Cause?
Article in Journal of ophthalmic & vision research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report a case of unexplained perivascular chorioretinal atrophy temporally associated with ranolazine use. Case Report: A 64-year-old man with chronic stable angina pectoris was referred to our retina clinic with a complaint of an inferior visual field defect in the right eye over the last 1 month. The symptom onset coincided with the prescription of ranolazine extended-release 500 mg daily and slowly progressed over this period. Central and color vision were normal, and relative afferent pupillary defect was negative. Fundus exam showed chorioretinal atrophy in both eyes along the main vascular arcades, which was more prominent in the right eye and along the superior temporal arcade. Visual field assessment disclosed a double arcuate scotoma in both eyes. Swept-source optical coherence tomography showed outer retina, retinal pigment epithelium, and choriocapillaris atrophy in the extrafoveal area. Fundus autofluorescence showed hypo-autofluorescence, and fluorescein angiography revealed staining along the vascular arcades. Electroretinogram disclosed abnormal photopic and scotopic responses. All findings were more prominent in the right eye and along the superior temporal arcade. Ranolazine intake was stopped. Three months after drug cessation, the patient's visual field and electroretinogram improved. Conclusion: This is the first case report on ranolazine-associated chorioretinal toxicity, highlighting the necessity of further studies on potential side effects of even short-term exposure to this drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.